Register for free
Recent Quotes
My Watchlist
Indicators
Business Insurance Index
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Articles published by jCyte, Inc.

jCyte Inc. Announces First Patients Treated in JC02-88 Trial for Retinitis Pigmentosa
From jCyte, Inc.
Via Business Wire
New Study Demonstrates Breakthrough with Retinal Progenitor Cell Therapy in a Preclinical Model of Photoreceptor Degeneration
From jCyte, Inc.
Via Business Wire
jCyte, Inc. Announces Positive Pre-Phase 3 FDA Type B Meeting and Outlines Plans to Start Pivotal Trial of jCell® for Retinitis Pigmentosa in the Second Half of 2024
From jCyte, Inc.
Via Business Wire
jCyte Announces Appointment of Dr. Stewart Craig as Chief Technology Officer
From jCyte, Inc.
Via Business Wire
jCyte Identifies Key Anatomical Biomarker Predictive of Substantial Restoration of Visual Function in Retinitis Pigmentosa Patients Treated With jCell Therapy
From jCyte, Inc.
Via Business Wire
jCyte Announces Appointment of Peter C. Kuper as Senior Vice President of Finance and Information Technology
From jCyte, Inc.
Via Business Wire
jCyte Announces Appointment of John Pollack, MD, FASRS, as Chief Medical Officer
From jCyte, Inc.
Via Business Wire
jCyte Announces Expansion of Role for Chief Commercial Officer Samir Mody
From jCyte, Inc.
Via Business Wire
jCyte Announces Appointment of R. Heath Coats as Vice President of CMC, Regulatory Compliance and Quality Control
From jCyte, Inc.
Via Business Wire
jCyte® Announces Appointment of Dr. Rebecca Kammer as Vice President of Clinical Operations
From jCyte, Inc.
Via Business Wire
jCyte Announces Appointment of Victor Chao as Vice President of CMC Operations
From jCyte, Inc.
Via Business Wire
jCyte Announces Appointment of Adrian Morris as Chief Development Officer
From jCyte, Inc.
Via Business Wire
jCyte Announces Appointment of Dr. Adam Walsh as Chief Financial Officer
From jCyte, Inc.
Via Business Wire
jCyte Announces Appointment of John Sholar as General Counsel
From jCyte, Inc.
Via Business Wire
jCyte, Inc. Identifies Retinitis Pigmentosa Patients Most Likely to Respond in Planned Pivotal Study with jCell Therapy
From jCyte, Inc.
Via Business Wire
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.

Business Insurance is a singular, authoritative news and information source for executives focused upon risk management, risk transfer and risk financing.

Never miss important news. Subscribe to our newsletter.
Register for free

Information

Copyright 2024. BUSINESS INSURANCE HOLDINGS